Diamond Biotechnology Co

Diamond Biotechnology Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Diamond Biotechnology Co (6815.TWO) as of Oct 18, 2026 is 4.58 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 4.79 % — a change of -4.34% (lower).

FCF Conversion

4.58 %

YoY

-4.34%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Diamond Biotechnology Co is 2025 4.58 % . FCF Conversion Rate (FCF/EBITDA) of Diamond Biotechnology Co was 2024 4.79 % . It decreases by -4.34% lower compared to the previous year.

The Diamond Biotechnology Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
40.38 TWD
Jan 1, 2019
14.93 TWD
Jan 1, 2020
128.51 TWD
Jan 1, 2021
-45.92 TWD
Jan 1, 2022
253.29 TWD
Jan 1, 2023
-333.18 TWD
Jan 1, 2024
4.79 TWD
Jan 1, 2025
4.58 TWD
The Diamond Biotechnology Co FCF Conversion history
YEARFCF ConversionYoY
4.58 %-4.34%
4.79 %-101.44%
-333.18 %-231.54%
253.29 %-651.56%
-45.92 %-135.74%
128.51 %+760.68%
14.93 %-63.03%
40.38 %-127.08%
-149.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Diamond Biotechnology Co Stock analysis

What does Diamond Biotechnology Co do? Diamond Biotechnology Co Ltd, based in Taipei City, Taiwan, operates in the Health Care sector. The company develops, manufactures, and sells skincare products such as facial masks, lotions, and creams, alongside medical equipment including sonic and radio wave devices, fat reduction systems, and consumables like botulinum and collagen injections. It also offers medical equipment leasing and beauty management consulting services. The firm serves domestic and international markets, having listed on 29 January 2021. Diamond Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Diamond Biotechnology Co stock

FCF Conversion Rate (FCF/EBITDA) of Diamond Biotechnology Co is 4.58 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Diamond Biotechnology Co changed from 4.79 % to 4.58 %, representing a -4.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Diamond Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Diamond Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Diamond Biotechnology Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Diamond Biotechnology Co